On July 12, 2025, the Biomedical Advanced Research and Development Authority (BARDA) issued Request for Proposals (RFP) #75A50125R00006. This RFP seeks proposals for the advanced development, FDA licensure, and procurement of vaccines targeting Marburg virus (MARV) and Sudan ebolavirus (SUDV). With recent outbreaks and the absence of licensed vaccines for these deadly filoviruses, BARDA’s initiative represents a critical investment in U.S. biosecurity.
BARDA aims to secure monovalent vaccines against MARV and SUDV through a multi-phase approach. The core objectives of this RFP include:
- Advanced development and licensure of a monovalent MARV and a monovalent SUDV vaccine
- Procurement and maintenance of up to 500,000 licensed regimens of monovalent vaccines against the same
- Up to 300,000 doses prelicensure of MARV and SUDV monovalent vaccines (Final Drug Product)
In addition to these core objectives, multiple option periods related to manufacturing, domestic facility production, Phase 4 post-marketing commitments, and pre- and post-licensure procurement are fully described in the RFP.
Key Dates to Remember
Offerors should be aware of the following critical deadlines:
- Questions Due: July 31, 2025 at 2PM ET
- Proposal Responses Due: August 26, 2025 at 2PM ET
Proposals include technical and business volumes as separate attachments and be fully compliant with all instructions outlined in Sections L and M of the solicitation.
Award Structure and Funding Information
This RFP outlines a multi-phase, hybrid contract model (Cost Plus Fixed Fee and Firm Fixed Price). The contract is structured with a five-year base period and five additional one-year option periods, not to exceed a total of 10 years.
A Strategic Step Toward Public Health Security
This BARDA initiative addresses a long-standing gap in the national medical countermeasure portfolio. With a history of high-fatality outbreaks, the MARV and SUDV viruses are a threat to both biodefense and global health. By investing in advanced development and stockpiling of vaccines, BARDA will ensure that the U.S. can respond rapidly to outbreaks or possible acts of bioterrorism involving these filoviruses.
If your company has considered applying for federal funding, your federal funding journey starts here. EverGlade Consulting is a national firm that helps organizations win and manage federal awards. We offer services ranging from Pursuit, Proposal and Post-Award support to comply with federal regulations at agencies including BARDA, ARPA-H, NIH, DTRA, JPEO, DOD, DIU, DOE, and DARPA.
